Hearther Daley, MD
Obstetrics · McAllen, TXNPI 1821065038
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $55,036 of the $56,591 with a category attached, or 97.3%. Kedplasma LLC accounts for 97.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $30,937 and has fallen 99.5% since, to $154 in 2024. Among obstetrics clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $505.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kedplasma LLC$55K
- AbbVie$511
- AMAG Pharmaceuticals, Inc.$188
- Duchesnay USA Incorporated$174
- Myovant Sciences Inc.$160
- Evofem Biosciences, Inc.$103
- plus $418 from 13 others
Across 11 payments — averaging $3622.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$40K
What the payments were for
- Consulting fees$55,03697%
- Food & beverage$1,4413%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kedplasma LLC | 45 | $55,036 |
| AbbVie(2 entities) | 25 | $511 |
| AMAG Pharmaceuticals, Inc. | 4 | $188 |
| Duchesnay USA Incorporated | 13 | $174 |
| Myovant Sciences Inc. | 4 | $160 |
| Evofem Biosciences, Inc. | 1 | $103 |
| Coopersurgical, Inc. | 2 | $88 |
| Exeltis, USA Inc. | 3 | $66 |
| BD | 2 | $42 |
| Bayer | 2 | $38 |
| Astellas Pharma US Inc | 1 | $29 |
| Cumberland Pharmaceuticals, Inc. | 2 | $24 |
| Organon | 2 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Merck | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Lupin Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,591 in reported general payments places this provider in the 95th percentile of 85 obstetrics providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 24 | $1,684 |
| Np ThyroidThyroid,pork | 16 | $839 |
| YuvafemEstradiol | 11 | $659 |
| ProgesteroneProgesterone, Micronized | 15 | $445 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $266 |
| Fluconazole | 25 | $169 |
| Metronidazole | 19 | $164 |
| NortrelNorethindrone-Ethin. Estradiol | 12 | $121 |
| Levothyroxine Sodium | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Other obstetrics in McAllen
- Laura FonsecaMcAllen$8K
- Sara MoufarrijHouston$52K
- Rene PerezSan Antonio$20K
- Lisa BourbeauAustin$11K
- Heather NevilleFort Worth$10K
- Erica GarzaAustin$9K
- Vagisha SharmaArlington$9K
- Liliana KanuPasadena$9K
- Caroline CohenAustin$8K
- Paul DenteFort Sam Houston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.